Research Shows Screening with X-rays Does Not Significantly Reduce Lung Cancer Mortality, Highlights Need for Additional Cancer Detection Tools Including EarlyCDT®-Lung

Share Article

Research recently published in the Journal of the American Medical Association (JAMA) found that annual screening with chest radiographs over a 4-year period did not significantly reduce lung cancer mortality. These findings are changing the way medical professionals diagnose and monitor lung cancer, shifting focus to alternative detection methods such as low dose CT scans or EarlyCDT®-Lung.

Finding lung cancer at its earliest stages
EarlyCDT-Lung is a cost-effective tool in conjunction with CT to assist physicians in finding lung cancer at earlier stages, when treatments are more effective.

Research published in the October 26, 2011 issue of the Journal of the American Medical Association (JAMA) conclusively proved that “annual screening with chest radiographs over a 4-year period did not significantly reduce lung cancer mortality.” The trial included more than 150,000 participants who underwent an annual chest radiograph for 4 years. These findings are changing the way medical professionals approach the diagnosis of lung cancer.

Oncimmune® (USA) LLC offers EarlyCDT-Lung, as an alternative to chest radiographs in the wake of recent research findings published in the Journal of the American Medical Association (JAMA). A simple blood test that aids physicians in the early detection of lung cancer, EarlyCDT-Lung is another option to help detect lung cancer early.

Founded in 2006, Oncimmune (USA) LLC is a pioneer in the development of early cancer detection techniques. Now available in all 50 states, EarlyCDT-Lung is transforming lung cancer detection methods in the United States. EarlyCDT-Lung is a commercially available blood test used to measure specific autoantibodes, or immunobiomarkers, which are elevated in patients with lung cancer. Because these autoantibodies are present at the earliest stages of the disease, EarlyCDT-Lung can be used to determine a patient’s lung cancer risk before a tumor is detected. This critical information can then aid in the early diagnosis of the disease, potentially before a patient exhibits specific symptoms of lung cancer.

CT scans are another screening method for those at risk for lung cancer. As reported in the landmark National Lung Cancer Screening Trials study (NLST) published in the NEJM in July 2011, early detection enabled by low-dose CT scans resulted in a 20% reduction in lung cancer mortality in a high risk patient population. Though this news is very positive in regard to early lung cancer detection, there are several issues associated with utilizing CT scans for lung cancer screening. These issues include: a high false-positive rate, a significant out-of-pocket cost for patients and radiation exposure.

As the results of these studies begin to shed more light on modern lung cancer detection techniques, Oncimmune will work with the medical and advocacy communities to see how EarlyCDT-Lung can be a valuable tool in finding lung cancer early. EarlyCDT-Lung offers an accuracy of more than 90% with one-seventh the false positive rate of CT scans, no radiation risk and a positive predictive value 3 times that of CT. Additionally EarlyCDT-Lung is covered by Medicare and variety of private health insurance companies.

“These research findings are a reminder to everyone in our field of the great need for continued development of better cancer detection technologies,” said Dan Calvo, President and CEO of Oncimmune. “EarlyCDT-Lung is a cost-effective tool in conjunction with CT to assist physicians in finding lung cancer at earlier stages, when treatments are more effective.”

The entire Oncimmune team is committed to finding new and innovative ways to diagnose lung cancer in its earliest stages. Recent efforts to promote Lung Cancer Awareness Month have helped the makers of EarlyCDT-Lung reach an even larger audience of consumers and medical professionals alike. Watch for more exciting announcements from Oncimmune as they work to revolutionize modern cancer detection methods.

About Oncimmune LLC

Oncimmune (USA) LLC, founded in 2006, is an industry leader in early cancer detection. The company is committed to advancing early cancer detection through proprietary immuno-biomarker technologies based on biological technology identified by John Robertson, M.D., Professor of Surgery at Nottingham University, England, and Chief Scientific Officer of Oncimmune LTD. Ongoing research and development is conducted by Oncimmune under the direction of Professor Robertson. The company’s mission is to develop early cancer detection tests to identify more than 90% of solid-tumor cancers, which make up 70% of all cancers including lung, breast, colorectal, prostate, stomach, pancreatic and ovarian. All testing is performed exclusively at Oncimmune’s CLIA (Clinical Laboratory Improvement Act) regulated laboratory located in the metro Kansas City area. Oncimmune (USA) LLC is a wholly owned subsidiary of Oncimmune LTD. Oncimmune LTD owns a portfolio of patents, including Patent Nos. 7,402,403 and 7,205,117, with five others currently filed and under review. For more information about Oncimmune, visit: http://www.hellohaveyouheard.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Greg Stanley
Visit website